Influenza Vaccination
LiteVax B.V. conducts clinical research in influenza vaccine development, with attention to safety, tolerability, and immunogenicity in healthy adults across different age groups.
- Adjuvanted influenza vaccines
- Healthy adult immunisation
- Age-related immune responses
The sponsor’s influenza programme includes interest in vaccine formulations designed to enhance immune responses while maintaining acceptable tolerability.
Pneumococcal Disease Prevention
The company also funds research in pneumococcal infection, focusing on pneumococcal conjugate vaccines and their ability to support protective immune responses in healthy participants.
- Pneumococcal conjugate vaccines
- Adjuvant-enhanced formulations
- Immune protection against bacterial respiratory disease
This area reflects a therapeutic interest in preventing bacterial respiratory illness through vaccine-based approaches.
Adjuvant Technology
Across its vaccine portfolio, LiteVax B.V. places emphasis on vaccine adjuvants and their role in shaping immune activation and response quality.
- Novel adjuvant formulations
- Immunological mechanisms
- Antigen-adjuvant combinations
Its research activity is centered on improving vaccine performance through adjuvant-based design in both viral and bacterial prevention.
Adult and Older-Adult Immunisation
LiteVax B.V. studies vaccine responses in healthy adults and older adults, highlighting interest in population-specific immune responsiveness and vaccine suitability across age ranges.
- Adult vaccination
- Older-adult immune response
- Comparative immunogenicity
This focus supports evaluation of how vaccine formulations perform in different demographic groups relevant to respiratory disease prevention.
